PharmaZell and Novasep enter into exclusive negotiations in new drive to create a technology-driven leader
PR91734
PharmaZell and Novasep enter into exclusive negotiations in new drive to create a technology-driven leader for complex small molecules and ADCs of global scale
RAUBLING, Germany and LYON, France, Sept. 16, 2021 /PRNewswire-=KYODO JBN/ --
PharmaZell, the German producer of highly resilient and specialty APIs, and
France-based Novasep, a leading CDMO focused on complex small molecules and
ADCs have entered into exclusive negotiations to create a leading European
platform in the attractive API manufacturing and CDMO space with a
complementary set of differentiated technologies and highly diversified base of
blue-chip pharma and biotech customers.
Novasep is a leading CDMO player developing and manufacturing complex small
molecules predominantly for pharma and biotech customers. The company leverages
a wide range of differentiated technologies including high energy and cryogenic
chemistries and industrial scale chromatography. It is a world leader in ADC
and HPAPI, fast-growing targeted cancer therapy segments.
Novasep's capabilities are highly complementary to PharmaZell's expertise in
the manufacturing of complex APIs requiring special handling procedures or
technologies. Combining the two businesses would create a leading, highly
diversified, and highly differentiated API manufacturing and CDMO platform. The
combined business would be able to draw from a comprehensive and broad
technology suite for complex molecules and a global production footprint to
support pharma and biotech customers over the complete lifecycle of a drug. The
combined business would generate nearly €500m of revenues and employ close to
2,000 employees across seven production and R&D sites in Europe (Germany,
France and Italy), two sites in India and one in the US.
The proposed transaction would be backed by PharmaZell's current majority
shareholder Bridgepoint. Bridgepoint Group PLC is the world's leading quoted
private assets growth investor focused on the middle-market with €27 billion
AUM and a local presence in the US, Europe and China.
The proposed acquisition remains subject to the fulfilment of customary
conditions precedent for this type of transaction including the information and
consultation of works councils and other regulatory approvals.
The Press release is available in pdf.
Photo - https://mma.prnewswire.com/media/1628012/Novasep_PharmaZell.jpg
Logo -
https://mma.prnewswire.com/media/1628011/Novasep_Passion_Smart_Processes_Logo.jpg
PDF - https://mma.prnewswire.com/media/1628027/PharmaZell_Novasep_ENG.pdf
Contact details:
press@novasep.com
SOURCE: Novasep
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。